Biochips Market Size, Share & Trends Analysis Report By Type (DNA Chips, Lab-on-chip, Cell Arrays), By End-use (Academic & Research Institutes, Hospitals & Diagnostics Centers), And Segment Forecasts, 2022 - 2030

Report Overview

The global biochips market size was valued at USD 7.92 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 13.35% from 2022 to 2030. Biochip is becoming a hotspot segment for emerging players to mature. This is attributed to the rising drug development, increasing adoption of personalized medicines, as well as next-generation sequencing (NGS). Innovation in the Lab-on-a-chip offerings along with the biomedical advancement for microfluidic-based devices is expected to contribute to the industry growth. LOC devices are expected to deliver rapid results at the initial diagnosis of infectious diseases. The technology is widely utilized in epidemiological studies.

The health crisis of the COVID-19 pandemic impacted the supply chain of the biochip and resulted in a mismatch of supply and demand levels. The product demand increased with support from academic institutions and biopharma companies. For instance, in January 2022, a group of researchers from The Czech Academy of Sciences (the CAS) developed a system with a biochip to detect the COVID-19 virus. According to the researchers, a biochip is as rapid as an antigen test and as accurate as PCR testing. The combination of biochip technology with various applications is projected to boost industry growth.

For instance, in March 2022, a U.S.-based startup, Nutcracker raised funds worth USD 167 million via series C to enhance the RNA manufacturing platform based on a biochip. The biochip-based platform is expected to support the advancement of RNA-based therapeutics. The biochip as well as nanoparticle delivery technology assist in establishing comprehensive isolated and automated manufacturing. In addition, the acceleration in the use of biochip applications including drug development, obligated several R&D institutions and R&D teams to design a cost-effective and efficient process. In 2021, more than 700 drugs were in-progress for targeting approximately 8,000 rare diseases.

Biochips are utilized for testing drugs before their clinical trials. In May 2022, Vienne University of Technology, TU Wien, innovated a biochip-based technology to manufacture tissue beads in precise sizes and commercialize them along with drugs through a thin channel. Moreover, the patent application for this technology has been submitted. However, the manufacturing cost of biochips can restrain the growth of the industry. The majority of microfluidic devices are made of ultraviolet lithography, an extremely complex and costly technique that requires trained professionals with specialized instruments.

The high cost of manufacturing creates high barriers for new players to enter the market and produce a wide range of alternatives for the end-users. The low level of awareness in the developing and under-developed regions about the utility of biochips is also a concerning factor for the industry. Over a few years, the quantity of biochip-based research by research and academic institutes in developing countries has decreased. Limited knowledge among emerging companies in the drug development and personalized medicine sector is projected to limit industry growth.

Type Insights

The DNA chips segment dominated the global industry in 2021 and accounted for the highest share of more than 39.50% of the overall revenue. They are majorly used in academic research and clinical diagnostic tests for numerous diseases. For instance, in November 2021, Roswell Biotechnologies, a San Diego biotech company, is developing a molecular microchip that can take the molecule of an individual and assess it. The technology is anticipated to change the techniques of disease detection, development of drugs, and monitoring of health. The company aims to use the chip to enhance DNA sequencing. In DNA chips, the cancer diagnosis and treatment segment held a significant share in 2021. Biochips are projected to replace traditional medical diagnostic tasks, including cancer detection.

They are inexpensive, rapid, and widely available, hence enabling advanced detection of cancer to occur in numerous localities. It also eases the adoption process of telemedicine in the market. Similarly, Singapore's Institute of Bioengineering and Nanotechnology have designed a biochip that can detect drug-resistant cancer cells. The Lab-On-chips (LOC), on the other hand, is expected to register the fastest CAGR during the projected period. Since the usage of LOC in the area of medicine is increasing, it is expected to assist in early diagnostics, drug patents, and personalized medicine. Hence, factors, such as low costs and low sample volumes, are expected to extend the use of LOC technology in point-of-care diagnostics in emerging countries.

End-use Insights

The biotechnology and pharmaceutical companies segment accounted for the highest revenue share of more than 55.90% in 2021. The companies are indulging in heavy R&D programs to integrate biochip technology in various health applications. Considering the competitiveness in the pharmaceutical market, the companies cannot afford to invest heavily in developing drugs that have the probability of failing FDA approval. However, biochips are anticipated to be a new pathway to the discovery and development of drugs. Biochips are employed to develop biomarkers in the process of drug discovery, primarily for Single Nucleotide Polymorphism (SNP) analysis and gene expression profiling.

On the other hand, the academic & research institutes' end-use segment is projected to register the highest growth rate from 2022 to 2030. The institutions are conducting R&D on the technology and exploring various applications for biochips. For instance, in January 2022, a team of professionals from the Universidad Carlos III de Madrid (UC3M), the Universidad Politécnica de Madrid (UPM), along with other institutions, designed an advanced biochip that eases the manufacturing process of in vitro skin in the labs. The device is expected to be used in the testing of medicine and cosmetics.

Regional Insights

North America dominate the global industry in 2021 and accounted for the largest share of more than 48.40% of the overall revenue. The region is expected to maintain the industry position during the forecast period owing to the rising initiatives of the government for enhancing R&D through tax credits. The high existence of biotechnology companies along with academic and research institutions in the region is anticipated to boost further technology advancements in the applications of biochips. In the U.S., R&D tax credit is a budgetary benefit provided by the central government by offering companies dollar-for-dollar cash saving for carrying-out research activities to innovate, develop, or enhance products, processes, formulas, or software.

It is observed that a company can be offered a tax credit of around 12-16% for every dollar. The Asia Pacific region is estimated to register the fastest growth rate during the projected period. The fast-paced growth of this region will be mainly driven by China and India. The key determinants of industry growth in the region are enhancing the approachability to the technologies, a large patient pool, and improvement in healthcare infrastructure. The increasing adoption of biochip technology outsourcing to emerging markets by mature players to lower overall production costs is also a significant factor driving the region’s growth.

Key Companies & Market Share Insights

The industry is an attractive market for investors, hence the ease of fundraising by startups has increased. The existing players are executing numerous strategies, such as developing the product for various applications, indulging in partnerships and strategic collaborations via mergers and acquisitions, and regional expansions, to expand their industry presence. For instance, in August 2022, Abbott announced the outcome of a research that used Abbott's i-STAT TBI Plasma test, a portable analyzer, to detect two biomarkers associated with brain injury in blood. The study concluded that the product can assist in projecting the recovery of a patient from a traumatic brain injury and offer important insights. Some of the key players in the global biochips market include:

• Abbott Laboratories

• Agilent Technologies, Inc.

• PerkinElmer, Inc.

• Fluidigm Corporation

• Illumina, Inc.

• GE Healthcare

• Bio-Rad Laboratories, Inc.

• Thermo Fisher Scientific, Inc.

• LI-COR, Inc.

• Molecular Devices, LLC. 

Biochips Market Report Scope

Global Biochips Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global biochips market report on the basis of type, end-use, and region.

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • DNA Chips

    • Cancer Diagnosis And Treatment

    • Gene Expression

    • SNP Genotyping

    • Genomics

    • Drug Discovery

    • Agricultural Biotechnology

    • Others

  • Protein Chips

    • Proteomics

    • Expression profiling

    • Diagnostics

    • HTS

    • Drug discovery

    • Others

  • Lab-on-chip

    • Genomics

    • IVD & POC

    • Proteomics

    • Drug Discovery

    • Others

  • Tissue Arrays

  • Cell Arrays

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Biotechnology And Pharmaceutical Companies

  • Hospitals And Diagnostics Centers

  • Academic & Research Institutes

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE